In a phase 1 trial of dual CD19/BCMA CAR-T therapy (Wang et al., Ann Rheum Dis 2024 [30]), six patients with multi-organ refractory SLE achieved complete clinical and serologic remission with sustained B-cell and plasma-cell aplasia up to 12 months and no grade ≥ 2 CRS or neurotoxicity. The gene discussed is CD19; the disease is systemic lupus erythematosus.